Comparing vancomycin drug given through bone and vancomycin drug given through blood in knee replacement patients
Phase 4
- Conditions
- Health Condition 1: M170- Bilateral primary osteoarthritis of kneeHealth Condition 2: M171- Unilateral primary osteoarthritisof knee
- Registration Number
- CTRI/2024/07/070301
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Any subject more than 18 years of age who is undergoing a primary TKR for osteoarthritis and
given consent for the procedure.
Exclusion Criteria
Past knee surgery (including knee scopes), allergy, patients with bleeding disorder and
immunocompromised and/or immunosuppressed patients (HIV, Hepatitis B/C, end stage renal
disease (ESRD), post-transplant, chemotherapy or radiation therapy, medications which are
immunomodulating).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method demonstrate the utility of intra osseous vancomycin over Intravenous Vancomycin in primary TKR with improved local tissue concentration and decreased systemic concentrations.Timepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method oneTimepoint: None